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Continuous ambulatory peritoneal dialysis impairs T lymphocyte se-
lection in the peritoneum. Peritoneal lymphocytes (PCL) of 45 healthy
individuals, four uremic patients with end-stage renal disease (ESRD) and
25 long-term continuous ambulatory peritoneal dialysis (CAPD) patients
were characterized by flow cytometry to investigate whether CAPD alters
the phenotype of PCL. B lineage cells constitute a minority of PCL (2.5%
ofcells). Although the majority of peritoneal T cells expressed a/3 T cell
receptor (TcR), 7% expressed 1'b TcR, a proportion which was signifi-
cantly higher than that in peripheral blood (PBMC) (approximately 4%).
The majority of PCL T cells exhibited markers of the thymus-dependent
lineage (CD2, CD3, TcRa/3, CD8a or CD4) and surface antigens
associated with memory and activation (CD45RO, CDI la, CD18, CD49d,
HLA-DR). An average of 75% of both CD4 and CD8 PCL T cells of
healthy subjects and CAPD patients were CDw6O1, thus characterizing
the T cell subset containing the helper activity for the mitogen-driven B
cell differentiation. CD44s was abundantly expressed on PCL T cells. In
contrast to PCL T cells of healthy subjects peritoneal T lymphocytes of
CAPD patients exhibited CD44 splice variants containing products of
cxon-v9 and the proportion of CD44v9 cells correlated with the fre-
quency of peritonitis episodes the patients had gone through. The majority
of PCL T cells of both healthy subjects and APD patients were CD8. A
large proportion of CD8 PCL T cells from healthy subjects expressed the
homodimeric CD8cnx isoform; however, such cells were not found in
CAPD patients. In healthy subjects mRNA for the recombination activat-
ing gene I (RAG-i) was detectable in a PCL population containing
CD7 CD34 and CD7CD34 cells. In contrast, neither mRNA tran-
scripts of the RAG-I gene nor CD34 cells were detectable in PCL of
CAPD patients.
The vascular and lymphatic systems supplying the peritoneal
membrane constitute an efficient system for solute delivery and
removal from the peritoneal cavity. This filtration capacity is
utilized in continuous ambulatory peritoneal dialysis (CAPD) for
the therapy of end-stage renal disease (ESRD) [I]. CAPD treat-
ment permanently exposes the peritoneum to nonphysiological
chemical stimuli (such as dialysate) and facilitates the access of
microorganisms into the peritoneal cavity. Additionally, in vitro
studies have shown that CAPD impairs peritoneal host defense
mechanisms [2—4].
The periphery of the immune system contains inhomogeneously
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distributed B and T cells whose phenotype, repertoire, develop-
mental origin, and function are highly divergent. Lymphocytes
that are targeted to different organs guided by a spatiotemporal
sequence of tissue-specific homing receptors, local induction or
selection processes are important in the diversification of periph-
eral lymphocyte compartments [reviewed in 5].
In recent studies the selection and differentiation mechanisms
of lymphocytes in the normal peritoneum have been investigated.
Studies have proven that the fetal human omentum is a site for the
lymphopoiesis of B lineage cells (CD5 B cells) [6]. Experiments
in normal as well as in experimentally manipulated mice revealed
differences in the phenotype and repertoire of peritoneal T
lymphocytes in comparison to other peripheral cells [7]. More-
over, these analyses provided evidence that the peritoneum
represents a microenvironment that favors the expansion or
accumulation or both of a unique T cell repertoire, and might
serve as a site for thymus-independent T cell differentiation [5,
8—10]. Recently we were able to confirm this hypothesis in studies
of lymphocytes from the adult human peritoneuni. We found that
also the human peritoneum could act as a microenvironment
capable of supporting both a thymus-independent differentiation
of T lymphocytes and the development of natural killer cells (NK
cells) [11].
In the omentum and under the parietal peritoneum lymphoid
and phagocytic cells are organized in cell aggregates termed milky
spots, and recently published data suggest that the 'milky spots' of
the peritoneum [12] support local macrophage generation [13,
14). CAPD treatment impairs peritoneal host defense mecha-
nisms. Alterations of first line defense mechanisms mediated by
peritoneal macrophages have been studied intensively [reviewed
in 4]. However, although the activation of macrophages via T cell
or NK cell derived y-interferon (y-IFN) leading to enhanced
microbicidal activity is a well recognized effect [15], the impor-
tance of T lymphocytes in peritoneal immune response mecha-
nisms during CAPD is unclear.
The aim of the present study was to analyze the influence of
CAPD-treatment on the phenotype of peritoneal T lymphocytes.
The results of our study show that the peritoneal T cell repertoire
of CAPD patients differs considerably from the corresponding
population of healthy subjects and we provide evidence of an
impaired differentiation of T lymphocytes in the CAPD perito-
neum.
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Table 1. List of CAPD patients included in the study
Initials Sex
Age
years Diagnosis
CAPD
months Infections Bacteria
Patients newly on CAPD
ST. A. f 62 idiop. amyloidosis 0 no no
St. Chr. m 34 diabetic nephrop. 0 no no
Str. M. m 25 IgA nephrop. 0 no no
S. D. f 19 chron. ON' 0 no no
Long-term CAPD patients
A. J.
B. M.-L.
B. J.
inf
m
51
50
60
IgA nephrop.
chron. GN
chron. GN'
42
48
58
6
8
3
a, b
a, b
b, f, g
D. H. m 65 polycystic kidn. 41 5 a, b
D. C. f 50 diabetic nephrop. 24 4 a, b
E. B.
E. R.1
f
m
55
59
interstit. nephr.
chron. GN'
52
51
3
2
a, b
a, b
E. R. 1 60 plasmocytoma 24 2 a, b
H. F. m 38 IgA nephrop. 72 4 a, b, c, h
K. 0. m 49 chron. GN 36 2 a
K. E. m 61 chron. UN' 56 3 b, f, g
K. P. m 53 membr. GN 60 4 b, g
K. A. f 55 goodpasture 54 4 a, b, c, d
L. A.1 f 57 idiop. amyloidosis 72 5 a, b
L. W. m 65 diabetic nephrop. 60 8 a, b, e, f
M. U. in 26 goodpasture 78 6 a, b, e
M. A.
v. M. H.
m
m
24
67
IgA nephrop.
chron. GN
36
52
6
4
a, b, c
a, b, c, d
M E. in 45 IgA nephrop. 84 3 b, 1, g
S. F. in 52 diabetic nephrop. 144 8 a, b, c, e
S. I. f 47 diabetic nephrop. 41 2 a
Sch. F m 67 chron. GN' 108 6 a, b
V. K.
W. A.
f
m
47
62
lupus nephritis
chron. GN
57
90
4
8
a, c
a, b
W. B. 1 50 chron. GN' 38 2 b
Bacteria detected during CAPD-peritonitis and/or exit-point infections: (a) S. aureus, (b) S. epidermidis, (c) E. coli, (d) Enterococci, (e)Acinetobacteria,
(1) Co,ynebacteria, (g) Pseudomonas aeruginosa, (h) Proteus mirabilis.
'Diagnosis based on clinical features; no confirmation through kidney biopsy.
In two patients the CD4/CD8 ration was similar to that of peripheral blood (CD4/CD8 > 1)
Methods
Patients and collection of cells
Peritoneal cells from normal subjects were obtained from 45
women (mean age 33 years; range 19 to 63 years) undergoing
diagnostic laparoscopy. Material from patients with pelvic inflam-
matory disease, endometriosis or cancer was excluded from the
study. During laparoscopy, care was taken not to contaminate the
peritoneal cavity with peripheral blood. A total of 100 ml of 0.9%
NaCI were instilled and removed under observation by gentle
suction.
Peritoneal cells were further obtained from 25 stable CAPD
patients and four patients with ESRD who had newly started on
CAPD (Table 1). No selection of CAPD patients was performed
on the basis of the underlying renal disease. None of the patients
was hospitalized or was given antibiotics or anti-inflammatory
medication, or had a history of peritonitis in the six months prior
to the study. Peripheral blood mononuclear cells (PBMC) were
prepared from heparinized blood by Ficoll density-gradient cen-
trifugation (Sigma, Munich, Germany).
Monoclonal antibodies
The various mAb (labeled with F1TC or PE) used for the
staining of cell surface markers were obtained from Dianova-
Immunotech [Hamburg, Germany; anti-CD2, -CD3, -CD4, -CD5,
-CD7, -CD8, -CD11a, -CD1Ib, -CD16, -CD18, -CD19, -CD2O,
-CD45RA, -CD45RO, -CD49d, -CD56, -HLA-DR, anti-HML-1,
goat anti-human 1gM (GaHIgM), goat anti-mouse Ig (GaMIg),
GaMIgM] and Becton Dickinson (Heidelberg, Germany; anti-
CD34, anti-TcR a13, anti-TcRy). The mAbs specific for CD843
and CD813 were gifts from E. Reinherz [16] and N. Flomenberg
[17]. The mAbs against CD44 s and CD44 splicing variants (exon
4v, 6v and 9v) were from U. GUnthert [18]. The mAb against
CDw6O (MT-32) was produced by P.E. Rieber.
Procedure for labeling cells for the use in flow cytometly (FCM)
Peritoneal cells were collected by centrifugation of the lavage
fluid or the dialysate and washed twice in RPM! 1640 culture
medium (5% FCS). Monocytes/macrophages and mesothelial
cells were depleted by adherence to plastic culture flasks. Non-
adherent cells were collected and filtered through a nylon mesh cell
strainer (70 .tm) to remove cell debris and aggregates. The cells were
suspended in PBS (1% BSA, 0.1% NaN3) at 2 X iO cells/100 jl, and
directly conjugated mAbs were added in volumes of 10 d each. The
staining of PBMC was performed in whole blood. After incubation
(30 mm at 4°C) PBMC and PCL samples were prepared in a Q-Prep
leukocyte preparation system (Q-Prep, Coulter Electronics, Krefeld,
Germany) in order to lyse erythrocytes and to fix stained cells. For
double staining with antibodies (anti-CD8a, -CD813, -CDw6O,
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Table 2. Phenotype analysis of PCL isolated from the peritoneal lavage fluid of normal subjects and CAPD patients, in comparsion with the
phenotype of PBMC lymphocytes
CD3 CD4d, e CD8d.C
CD19
CD2O
CD16/
CD56 TCRa/ TCRyI HLADRt HML-1°
PBMCC 72 47 28 12 18 64 4 8 <1
range 66—76 37—54 22—33 8—16 12—32 44—76 1—13 6—10 —
PCLC 77 25 54 2 45 68 7 48 4
range 57—88 21—33 40—70 <1—5.5 38—52 57—81 2—17 40—54 1—7
PCLU (CAPD) 74 40 47 3 34 66 7 53 3
range 60—92 23—75 25—69 <1—8 18—48 61—87 2—16 44—62 1—6.5
The phenotype of PBMC lymphocytes did not differ between healthy subjects and CAPD patients. It has to be noted that not all listed parameters
were examined in every cell sample; however, the analysis of each parameter was repeated in corresponding PBMC and PCL samples of at least 7
different individuals.
C Percentage of cells labeled with the various mAb used (mean % and range of % from all cell samples).h Percentage of both CD4 and CD8 T lymphocytes expressing HLA-DR
C Percentage of CD3 T lymphocytes expressing the HML-1 antigend By double immunofluorescence the proportion of CD4CD8 DP cells in PCL of healthy subjects was found to be 5% (range 3%—8%), in CAPD
patients 3% (range 1%—5%); in PBMC of both healthy subjects and CAPD patients the percentage was 2% (range <1%—3%)
C By dual color immunofluorescence the proportion of CD4CD45RA was estimated to be 12% in PCL and 47% in PBMC; in PCL 91% were
CD4CD45RO and 50% in PBMC; in PCL 33% were CD8CD45RA and 69% in PBMC; in PCL 74% were CD8CD45RO and 32% in PBMC.
Equivalent results were obtained in CAPD patients.
-CD44 and -CD44 splice variants) which were not available in the
form of directly conjugated mAb, the labeling with these antibodies
was performed on cell suspensions, followed by incubation with
PE-GaMIg [10 uJ PE-GaMIg F(ab')2, 1% BSA, 0.1% NaN1] and
subsequently with FITC anti-CD8a, anti-CD3 or anti-CD56 after
washing the cells with PBS [5% normal mouse serum (NMS), 0.1%
NaN3]. The mAb reacting with the CDw6O antigen was stained with
a PE-labeled GaMIgM (1:500 in PBS, 1% BSA).
Flow cytometric analyses
All analyses were run on a FACStar Fluorescence Activated
Cell Sorter, using Lysis II software (Becton Dickinson) for both
acquisition and analysis of data. The instrument settings were
adjusted to an appropriate isotype control, and 10,000 events were
collected in a list-mode format.
Expression of the recombination activating gene-i (RAG-i) in
peritoneal lymphocytes
Poly(A) RNA was isolated directly from the cell preparations
with the aid of magnetic (dT)25 polystyrene beads (Dynabeads
mRNA Direct Kit; Dynal, Hamburg, Germany) and used for solid
phase eDNA synthesis employing the cDNA First Strand Synthe-
sis Kit (Pharmacia, Freiburg, Germany). The solid phase eDNA
was then used for the PCR amplification of RAG-I eDNA
transcripts. Oligonucleotide primers were synthesized (sense
primer; 5'CCAAAYTGCAGACATCTCAAC3', bp 50 to 74; an-
tisense primer, 5'CAACATCTGCCTTCACATCGATCC3', bp
591 to 614), which span the intron of the RAG-i gene so that
genomic DNA cannot be polymerized as a PCR product of the
correct size. A total of 95 l of PCR buffer containing 2 mol/liter
of each of the NTP's, 50 pmol/liter of each of the 5' and 3' primers
and 2.5 U Taq DNA polymerase was added to 5 j.d of the RT
reaction mixture. The mixture was amplified using a Thermal
cycler (Perkin Elmer, Weiterstadt, Germany) for 35 cycles (dena-
turation 60 seconds at 94°C, annealing 60 seconds at 58°C and
extension 90 seconds at 72°C). Ten microliters of PCR products
were electrophoresed through 2% agarose gel (Bio Rad, Munich,
Germany) and visualized with ethidium bromide. To confirm the
specificity of the RT-PCR products, they were transferred to
Hybond-N nylon membranes (Amersham, Braunschweig, Germa-
ny). The filters were hybridized with the internal RAG-i oligonucle-
otide probe (5'GCAAGAGGCAAAGCGATCCA3') end-labeled
with digoxigenin-ddUTP (DIG Labeling and Detection System,
Boehringer Mannheim, Germany). For hybridization and washing
procedures, buffer systems recommended by the manufacturer of the
'DIG-system' were used. Following hybridization the DIG-labeled
oligonucleotide probes were detected by alkaline phosphatase la-
beled anti-DIG antibodies and 3-(2'-Spiroadamantan)-4-Methoxy-4-
(3'-Phophoryl-oxy)-Phenyl-1,2-Dioxetan) (AMPPD). The AMPPD
served as the substrate for subsequent detection of chemilumines-
cence reaction which was captured on conventional X-ray film.
Results
Phenotype of peritoneal cavity lymphocytes
The results of the phenotype analyses of PCL are summarized
in Table 2. The proportion of B lineage cells in PCL was 2.5%
both in healthy subjects and CAPD patients. On average 77% of
PCL of normal subjects and CAPD patients were CD3 and the
preponderance of T cells used the a/3 T cell receptor (TcR);
however, the percentage of TcR y T cells was increased
compared to that found in PBMC. The CD4/CD8 ratio was
inverted and the vast majority of both CD4 and CD8 T cells
expressed the CD45RO isoform of CD45. In contrast to the
results in normal subjects the proportion of CD4 and CD8 PCL
exhibited considerable variation between individuals in CAPD
patients. In two patients (Table 1) the CD4/CD8 ratio was similar
to that of peripheral blood (CD4/CD8 > 1).
To examine the expression of integrin adhesion molecules on
PCL the cells were stained with anti-CD3 in combination with
mAbs directed against different integrin adhesion molecules. In
Figure 1 a representative example of n1f32 [CD11a/CD18 (LFA-
1)] integrin expression is shown. Equivalent results were obtained
for the /31 integrin [a4f31 (VLA-a4, CD49d)] (data not shown).
Surface levels of amJ32 [CD1Ib/CD18 (Mac-i, CR-3)] on PCL T
cells were comparable to the findings in PBMC (Fig. 1). As can be
(I)
a)0
0
G)
E
=
a)
a)
Fig. 1. Dual color FCM was performed on
lymphocytes by staining the cells with anti-CD3
and mAbs against either of CDIJa, CDIJb and
CD18. Double positive cells were electronically
gated and the expression of CD11a, CD11b,
and CD18 on CD3 PCL reveals a single peak
of positive cells. The negative isotype control is
marked by an asterisk (*), The expression of
CD11a, CD11b, and CD18 did not differ
between healthy subjects and CAPD patients. A
representative example is shown.
seen from the figure, only a single population of cells expressing
high levels of CD11a/CD18 was found in peritoneal CD3 PCL
whereas among CD3 PBMC two populations of cells exhibiting
high and low receptor density, respectively, could be detected.
The expression of 137 integrin [aIELI37 (HML-1 antigen)] was
examined in order to investigate the dependence of PCL on
intestinal epithelial lymphocytes (IEL). Staining of CD3 PCL
with anti-HML-1 revealed that approximately 5% of T cells
expressed the HML-1 antigen at low receptor density (expressed
by < 1% of PBMC T cells and 80% of IEL) [19]. In summary,
the expression of a and /3 integrins (al/32, a4f31, am132, aJEL/37)
did not differ significantly between the three groups of patients
(normal subjects, ESRD patients newly on CAPD, and stable
long-term CAPD patients).
The majority of peritoneal T cells express CDw6O
The CDw6O antigen has been identified as the 0-acetylated
disialosyl group that is expressed on various gangliosides [20].
CDw6O is found on thrombocytes and on up to 40% of CD4 T
cells and 30% of the CD8 T cells from peripheral blood. The
CDw60 subset of both CD4 and CD8 T cells contains most of
the helper activity for the mitogen-driven B cell differentiation
[21]. In previous analyses of PCL from healthy subjects we had
shown that an average of 76% (range 62% to 92%) of both CD4
T cells and CD8 T cells were CDw60 [11]. When CAPD
patients were examined we found that in both groups of patients
(ESRD patients newly on CAPD and stable long-term CAPD
patients) the proportions of PBMC and of PCL T cells expressing
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CDw6O (mean of 79% of CD4 PCL, range 64% to 88%; mean of
72% of CD8 PCL, range 50% to 89%) were comparable to
healthy subjects (Fig. 2).
PCL T cells express CD44s and subsets of CAPD-PCL T cells
express CD44 splice variants
The cell surface glycoprotein CD44s is a broadly distributed
adhesion receptor for extracellular matrix molecules (that is,
hyaluronic acid) involved in leukocyte migration, T cell activation,
cell-cell interactions and metastasis formation [reviewed in 18].
Ten differentially spliced exons (exon-vi to vlO) encoding a
portion of the extracellular domain of CD44 give rise to a number
of variant isoforms of the receptor (CD44v). CD44s was abun-
dantly expressed on PBMC and PCL T cells of both healthy
subjects and CAPD patients. In PBMC of healthy subjects and
CAPD patients and in PCL of healthy subjects T cells expressing
PBMC PCL
102.
101
100
CD4
1 o
102
101w0
ci)0
o )
a)0,
0
C)0
-J
1 o
1 o
102
101
100
io
io
102
101
100
1o
io
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101
100
1o
1 o
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101
100
100 101 102 io io
100
100 101 102 io io
CD8
1 o
102
101 -
100
CAPD
patient
100 101 102 io io 100 101 102 io
CD4
1 o
1 o
102
101
100
100 101 102 io io 100 101 102 io io
COB
Log10 fluorescence FITC
Fig. 2. Dual color cytofluorographic analysis of
the expression of CDw6O on CD4 and CD8 T
cells from PBMC and PCL of normal subjects
and CAPD patients. Representative examples of
one normal subject and one CAPD patient are
shown.
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CD44v were not detectable to any notable degree (data not
shown). In contrast to that, PCL of CAPD patients comprised a
considerable proportion of T cells that exhibited CD44 splice
variants containing a domain encoded by exon-v9. The expression
of CD44v9 did not correlate with the duration of CAPD; however,
in patients who had gone through frequent episodes of CAPD
peritonitis (> 4 episodes) the proportion of CD44v9 T cells was
considerably increased compared with patients with rare episodes
of CAPD peritonitis (Fig. 3).
Peritoneal T lymphocytes of CA PD patients express the CD8of3
heterodimer and do not contain mRNA for the recombination
activating gene-i (RAG-I)
CD8 is expressed on the surface of T cells as either disulfide-
linked aa homodimer or cs/3 heterodimer. Thymus-derived T cells
express the CD8a/3 hcterodimer, whereas extrathymically derived
CD8 cells such as intestinal epithelial lymphocytes (IEL) and
natural killer cells (NK cells) express the CD8&a homodimer.
Previous analyses showed that a large proportion of CD8 PCL T
cells of healthy subjects exhibited the CD8aa homodimer. More-
over, PCL of healthy subjects that were depleted of B lineage cells
contained mRNA transcripts for the recombination activating
gene RAG-i [11], Messenger RNA transcripts of the RAG-i gene
are transiently expressed only in pro/pre B cells rearranging
immunoglobulin genes [22, 23] and immature T cells rearranging
T cell receptor [24]. Thus, the presence of mRNA transcripts of
RAG-i in PCL T lymphocytes is compatible with the hypothesis
of a thymus-independent T cell selection occurring in the healthy
peritoneal immune compartment.
To test whether CAPD interferes with this function CAPD-
PCL T lymphocytes were studied for the presence of cells
expressing CD8aa and were examined for mRNA transcripts of
the RAG-i gene. To distinguish between the two dimers of CD8,
double staining of PCL was carried out with both FITC-anti-
CD8a and PE-anti-CD8csf3 or PE-anti-CD813. In contrast to our
findings in healthy subjects, T cells expressing CD8aa were not
detectable in CAPD-PCL to any notable degree (Fig. 4). Further-
more, by applying RT-PCR we failed to detect mRNA transcripts
of RAG-i in CAPD-PCL T cells from the ESRD patients newly
on CAPD and from all long-term CAPD patients. Amplification
of mRNA from thymus and from PCL T cells of healthy subjects
yielded PCR products of the expected size (Fig. 5). These results
were confirmed by Southern hybridization of the PCR amplified
samples to examine the specificity of the PCR products by using a
RAG specific oligonucleotide probe internal to the predicted
PCR product (data not shown).
Discussion
The human fetal omentum has been demonstrated to be a site
for the Iymphopoiesis of B lineage cells [6]. In recent investiga-
tions of peritoneal T cells of healthy adult individuals, subsets of
T lymphocytes containing mRNA for the recombination activat-
ing gene-i (RAG-I) could be localized within the
CD2 CD3CD4CD8CDI 6CD56 cell population. The ma-
jority of these cells were CD7, and an appreciable proportion
expressed the stem cell marker CD34 with or without coexpres-
sion of CD7 [Ii]. Thus, subsets of PCL T lymphocytes were found to
exhibit characteristics of T cells selected independent of the thymus.
Moreover, the CD34 PCL do generate myeloid CFUs with a very
low cloning frequency (Fricke and Straka, unpublished observation).
The CD7--CD34 CD2CD3CD4CD8CD16CD56 pheno-
type has been described for a bipotential TINK-cell progenitor
recently identified in the human fetal thymus [25]. In contrast to
previously published results [261 we found that PCL comprise a large
proportion of mature NK cells. Hence, provided that NK progenitors
are present among PCL, they could differentiate into mature NK
cells under the influence of the peritoneal microenvironment.
In contrast to the findings in the normal peritoneum, cells
expressing CD34 or mRNA transcripts of the RAG-i gene and
cells expressing the homodimeric CD8a receptor were undetect-
able in PCL of CAPD patients. Since the changes of the perito-
neal lymphocyte population described above could also be ob-
served in patients newly started on CAPD, the possibility exists
that uremia itself could impair lymphopoiesis occurring in the
peritoneal immune compartment. Impairment of T lymphocyte
function is an established finding in chronic renal failure [re-
viewed in 27]. However, the peritoneal immune compartment
supporting thymus-independent T cell differentiation as well as
the way by which uremia and/or CAPD could interfere with these
mechanisms remain to he characterized. The surface of the
peritoneum is lined by mesothelial cells (MC) which do not
express E-selectin, factor VIII antigen, CD31, and cadherin-5
[281. Mesothelial cells produce a variety of cytokines such as
granulocyte (G)-CSF, granulocyte/macrophage (GM)-CSF, mac-
rophage (M)-CSF, iL-i 13, IL-6, IL-8 and TNF-a, and are activated
by IFN-y and TNF-a and stimulated to proliferate by IL-I
[28—301. In the omeritum and under the parietal peritoneum a
formation of variable loose aggregates of macrophages and lym-
phoid cells termed 'milky spots' has been described [12, 31]. In the
(hu-PBL-SCID)-xenotransplantation model human lymphocytes
injected to reconstitute a chimeric immune system exhibit an
accumulation in the peritoneum very similar to milky spots [321.
These lymphoid aggregates are predominantly formed by
CD3 CD8 HLA-DR T cells. In a recent study Suassuna et al
[26] demonstrated that phagocytes and T lymphocytes do not
show a random distribution in the peritoneal membrane, but are
organized in a perivascular spatial proximity. Taken together,
'milky spots' or perivascular aggregates of lymphoid cells or both
could represent sites of T cell differentiation in the peritoneum.
This assumption, however, needs to be confirmed by in situ
examination of peritoneal tissue.
Although there is evidence that subpopulations of peritoneal T
cells are selected in the immune microenvironment of the normal
peritoneum independent of the thymus, the majority T lympho-
cytes express a thymus-dependent phenotype and must have
migrated to the peritoneum as mature cells. Lymphocytes migrate
to different organs guided by a spatiotemporal sequence of
tissue-specific homing receptors [reviewed in 5]. The adhesion
molecule CD44 plays a pivotal role in lymphopoesis, lymphocyte
differentiation [33—35] and migration of lymphocytes into second-
ary and tertiary lymphoid organs [all reviewed in 36]. These
diverse functions have been shown to be attributed to different
isoforms of CD44 (termed CD44v) generated by alternative
splicing of the nuclear RNA [reviewed in 18]. In contrast to the
abundant expression of CD44s, variants of CD44 are expressed on
normal resting T lymphocytes only at very low levels. T cell
activation either by mitogen, anti-CD3 or specific antigen leads to
a transient up-regulation of variant CD44 glycoproteins [37].
Peritoneal T lymphocytes from healthy subjects were not found
Fig. 3. A. FCM analysis of expression of CD44s
and CD44v9 on CD3 PCL of healthy subjects
and CAPD patients. Peritoneal T cells
abundantly express CD44 s at high receptor
density. Expression of CD44v9 was detetctable
only on CAPD PCL. The isotype control is
marked by an asterisk (*)• Representative
examples are shown. B. Expression of CD44v9
on PBMC and PCL T cells from all CAPD
patients (each dot represents one patient).
CD44v9 was not expressed on PBMC T cells.
The proportion of CD3 PCL expressing
CD44v9 containing splicing variants was
increased in CAPD patients with a high
frequency of peritoneal infections (> 4 events
of CAPD peritonitis).
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to exhibit CD44v to any observable degree. In contrast, we
detected a substantial proportion of T cells among CAPD-PCL
that exhibited CD44 splice variants containing exon-v9. Both
uremic metabolism and CAPD-treatment could interfere with
mRNA splicing and cell surface expression of CD44. Insertion of
B
I
$
v-exons modulates the ligand binding properties of CD44 [38].
Since CD44s was shown to be of fundamental importance for the
interaction between T cells and endothelium [39], an altered
expression of CD44 could affect the activation and migration of T
lymphocytes in the CAPD peritoneum. Expression of CD44v
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increases in response to inflammatory cytokines [40]; neverthe-
less, CD44v is not merely a marker of non-specific inflammation
[41]. In a rat metastasis model certain CD44v isoforms containing
exon-v6 are causally involved in metastasis formation [42]. Up-
regulation of exon-v9 isoforms in gastric and renal cell carcinomas
relates to a poor prognosis of patients [43, 44]. In non-Hodgkin's
lymphomas CD44v9 was detectable on highly malignant T cell
lymphomas, and expression of v6 containing isoforms was found
to be an independent prognostic factor indicating an adverse
prognosis [45]. Taken together, these results indicate that expres-
sion of CD44v isoforms on inflamed tissue and tumor cells relates
to adverse effects of the diseases.
The detection of increased proportions of CD44v9 PCL T
cells in CAPD patients with frequent peritoneal infections fits into
this hypothesis. Therefore, it should be of interest to examine
whether expression of CD44v on PCL T cells reflects a marker for
adverse effects of CAPD therapy and hence could be a parameter
for the monitoring of therapy or prognostic evaluation.
The vast majority of CD4 and CD8 ' PCL T lymphocytes of
Fig. 4. Dual color FACS analysis of CD8 T
cells from PCL of a healthy subject and a CAPD
patient and PBMC. Cells were stained with anti-
CDRa (mAb B9.11; x-axis, FITC-Iabeled) and
anti-CD8cr3 (mAb 2ST8.5H7; y-axis, PE-
labeled). CD8aa T cells (lower right quadrant)
were absent in PBMC of healthy subjects and
CAPD patients. The average of CD8aa of the
CD8 population of peritoneal T cells in
healthy subjects was 20%. The proportion of
PCL CD8aa in the present example was higher
than the average. No CD8aa cells were found
in PCL from CAPD patients. Staining with anti-
CD8i43 (mAb 2ST8.5H7) or CD8/3 (niAb 2F5)
gave similar results. (Cells found in 1 are
nonspecifically stained by PE-GaMIg).
Representative examples of one normal subject
and one CAPD patient are shown.
both healthy subjects and CAPD patients expressed the CDw6O
antigen. On the basis of findings that CDw60 T cells accumulate
in inflamed tissues [46, 47], it had been postulated that CDw6O is
involved in the underlying inflammatory process. No subject
(neither healthy individuals nor CAPD patients) included in our
study had endometriosis or manifestations of inflammatory or
malignant disease in the peritoneal cavity. Thus, given the results
of our present study, we would favor the conclusion that CDw6O
is primarily involved in T cell differentiation [48] and probably
interacts with lectin-like receptor(s) involved in T cell activation
and migration to the peritoneum. In accordance with this hypoth-
esis is our observation of an unchanged expression of CDw6O on
PCL of the two CAPD patients with a ratio> 1 of CD4ICD8PCL
T cells (Table 1). Recently, the CDw6O antigen has been identified
as the marker for the helper T cell fraction both among CD4 and
CD8 T cells .[21]. However, with regard to the large number of
CD4 and CD8 T cells expressing a 'memory helper' phenotype
(CD45ROCDw60), the discrepancy in the proportion of pen-
toneal B and T cells is striking.
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Fig. 5. RAG-I mRNA detection by ethidium
bromide staining after PCR amplification of
cDIVA from thymus (1), B cell depleted PBMC
(2), and B cell depleted PCL of normal subjects
(3, 4), uremic controls newly started on CAPD (5
to 7) and long term CAPD patients (8 to 11). All
PCR reactions were repeated with identical
results; the C gene segment of the TcR a-chain
was successfully amplified from all PBMC and
PCL mRNA preparations.
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In conclusion, we detected T lymphocytes expressing a pheno-
type characterizing thymus-independent T cell selection in the nor-
mal peritoneum; however, such cells were undetectable in PCL from
CAPD patients. As a consequence of the latter finding the loss of
the CD8acs subset of NK cells (CD3CD8aCD16CD56)
resulted in a significantly diminished natural killer activity of perito-
neal NK cells of CAPD patients (Fricke H, Falk Chr, manuscript in
preparation). Moreover, PCL of CAPD patients who had gone
through frequent peritoneal infections comprised a significant pro-
portion of T cells expressing CD44 variant molecules which have
been demonstrated to be related to adverse effects in infiammatoty
and malignant diseases. The importance of peritoneal lymphocytes
for local specific immune response mechanisms is beyond doubt.
Nevertheless, the functional contribution of the peritoneal immune
compartment to the peripheral immune system and its alteration by
uremia and/or CAPD await further studies.
Acknowledgments
This work was supported by a grant of the Else Kröner-Fresenius-
Stiftung to H. Fricke. The authors thank Ursula GUnthert, Ellis Reinherz
and Neil Flomenberg for the gift of antibodies and P.C. Scriba for constant
support.
Reprint requests to Dr. Harold Fricke, Department of Medicine, University
of Munich, Ziemssenstrasse 1, 80336 Munich, Germany.
References
1. NOLPH KD: Continuous ambulatory peritoneal dialysis as long-term
treatment for end-stage renal disease. (editorial) Am J Kidney Dis
17:154—157, 1991
2. KEANE WF, COMTY CM, VERBRUGH HA, PETERSON PK: Opsonic
deficiency of pcritoneal dialysis effluent in continuous ambulatory
peritoneal dialysis. Kidney mt 25:539—543, 1984
3. BETJES MG, TUK CW, STRUIJK DG, KREDIET RT, ARIsz L, HOEFSMIT
EC, BEELEN RH: Immuno-effector characteristics of peritoneal cells
during CAPD treatment: A longitudinal study. Kidney mt 43:641—648,
1993
4. HOLMES CJ: Peritoneal host defense mechanisms in peritoneal dialy-
sis. Kidney mt 46(Suppl 48):S58—S70, 1994
5. KROEMER G, CUENDE E, MARTINEZ C: Compartmentalization of the
peripheral immune system. .4dv Immunol 53:157—216, 1993
6. SOLVASON N, KEARNEY JF: The human fetal omentum: A site of B cell
generation. J Exp Med 175:397—404, 1992
7. HAYAKAWA K, HARDY RR: Murine CD4+ T-cell subsets. Immunol
Rev 123:145—168, 1991
8. I5HIDA I, VERBEEK S, BONNEVILLE M, ITOI-JARA S, BERN5 A,
TONEGAWA S: T-cell receptor gamma delta and gamma transgenic
mice suggest a role of a gamma gene silencer in the generation of
alpha beta T cells. Proc NatlAcad Sci USA 87:3067—3071, 1990
9. BONNEVILLE M, ITOHARA S, KRECKO EG, MOMBAERTS P, ISI-IIDA I,
KATSUKI M, BERNS A, FARR AG, JANEwAY CJ, TONEGAWA S:
Transgenic mice demonstrate that epithelial homing of gamma/delta
T cells is determined by cell lineages independent of T cell receptor
specificity. JExp Med 171:1015—1026, 1990
10. ANDREU SJ, MORENO DE AT, MARCOS MA, SANCHEZ MA, MARTINEZ
AC, KROEMER G: Interleukin 2 abrogates the nonresponsive state of
T cells expressing a forbidden T cell receptor repertoire and induces
autoimmune disease in neonatally thymectomized mice. J Exp Med
173:1323—1329, 1991
11. HARTMANN J, MAA13EN V, RIEBER P, FRICKE H: T Lymphocytes from
the normal human peritoneum are phenotypically different from their
counterparts in peripheral blood and subsets of CD3-Iymphocytes
contain mRNA for the recombination activating gene RAG-i. EurJ
Immunol 25:2626—2631, 1995
12. BoRlsov AV: Lymphatics capillaries and blood vessels of milky spots
in the human greater omentum. Fed Proc 23:150, 1964
13. RATAJCZAK MZ, JASKULSKI D, POJDA Z, WIKTOR-JEDRZEJCZAK W:
Omental lymphoid organ as a source of macrophage colony stimulat-
ing activity in peritoneal cavity. Clin Exp Immunol 69:198—203, 1987
14. WIJFFELS JF, HENDRICKX RJ, STEENBERGEN JJ, EESTERMANS IL,
BEELEN RH: Milky spots in the mouse omentum may play an
important role in the origin of peritoneal macrophages. Res Immunol
143:401—409, 1992
15. NATHAN CF, MURRAY HW, WIEBE ME, RUBIN BY: Identification of
interferon-gamma as the lymphokine that activates human macro-
phage oxidative metabolism and antimicrobial activity. J Exp Med
158:670—689, 1983
16. SHIUE L, GORMAN SD, PARNE5 JR: A second chain of human CD8 is
expressed on peripheral blood lymphocytes. JExp Med 168:1993—2005,
1988
17. DI SANTO J, TERRY LA, FLOMENBERG N: Generation of anti-human
CD8 beta-specific antibodies using transfectants expressing mixed-
species CD8 heterodimers. J Immunol Meth 141:123—131, 1991
18. GUNTI-IERT U: CD44: A multitude of isoforms with diverse functions.
Cun' Top Microbiol Immunol 184:47—63, 1993
19. JARRY A, CERF BN, BROUSSE N, SELZ F, GUY GRAND D: Subsets of
CD3 + (T cell receptor alpha/beta or gamma/delta) and CD3-lympho-
cytes isolated from normal human gut epithelium display phenotypical
features different from their counterparts in peripheral blood. Eur J
Immunol 20:1097—1103, 1990
20. KNIEP B, PETER KJ, FLEGEL W, NORTHOFF H, RIEBER EP: CDw 60
antibodies bind to acetylated forms of ganglioside GD3. Biochem
Biophys Res Commun 187:1343—1349, 1992
21. RIEBER EP, RANK G: CDw6O: A marker for human CD8+ T helper
cells. J Exp Med 179:1385—1390, 1994
22. MELCHERS F, ROLINK A, GRAWUNDER U, WINKLER T, KARASUYAMA
H, GHIA P, ANDERSON J: Positive and negative selection events during
B lymphopoiesis. Curr Opinion Immunol 7:214—227, 1995
23. OE'I-rINGER MA, SCHATZ DG, GORKA C, BALTIMORE D: RAG-i and
RAG-2, adjacent genes that synergistically activate V(D)J recombi-
nation. Science 248:1517—1523, 1990
24. TURKA LA, SCHATZ DG, OETITINGER MA, CHUN JJ, GORKA C, LEE K,
MCCORMACK WT, THOMPSON CB: Thymocyte expression of RAG-i
and RAG-2: Termination by T cell receptor cross-linking. Science
253:778—781, 1991
25. SANCHEZ MJ, MUENCI I MO, RONCAROLO MG, LANIER LL, PHILLIPS
JH: Identification of a common T/natural killer cell progenitor in
human fetal thymus. JExp Med 180:569—576, 1994
26. SUASSUNA JHR, DAS-NEVES FC, HARTLEY RB, OGG CS, CAMERON
JS: Immunohistochemical studies of the peritoneal membrane and
infiltrating cells in normal subjects and patients on CAPD. Kidney mt
46:443—454, 1994
27. CHATENOUD L, JUNGERS F, DESCAMPS LB: Immunological consider-
ations of the uremic and dialyzed patient. Kidney mt 45(Suppl
44)92—96, 1994
28. JONJIC N, PERI G, BERNASCONI S, SCIACCA FL, COLOTFA F, PELICCI P,
LANFRANCONE L, MANTOVANI A: Expression of adhesion molecules
and chemotactic cytokines in cultured human mesothelial cells. J Exp
Med 176:1165—1174, 1992
29. LANFRANCONE L, BORASCHI D, GHIARA P, FALINI B, GRIGNANI F,
PEEl G, MANTOVANI A, PELICCI PG: Human peritoneal mesothelial
cells produce many cytokines (granulocyte colony-stimulating factor
[CSF], granulocyte-monocyte-CSF, macrophage-CSF, interleukin-1[IL-i], and IL-fl) and are activated and stimulated to grow by IL-i.
Blood 80:2835—2842, 1992
30. TOPLEY N, BROWN Z, JORRES A, WESTWICK J, DAVIES M, COLE5 GA,
WILLIAMS JD: Human peritoneal mesothelial cells synthesize inter-
leukin-8. Synergistic induction by interleukin-1 beta and tumor necro-
sis factor-alpha. Am JPatho! 142:1876—1886, 1993
31. SHIMOTSUMA M, KAWATA M, HAGIWARA A, TAKAHASHI T: Milky
spots in the human greater omentum. Macroscopic and histological
identification. Acta Anat (Base!) 136:211—216, 1989
32. HOFFMANN FG, KRANZ B, GALL C, THIERFELDER S: Peritoneal
sanctuary for human lymphopoiesis in SCID mice injected with
human peripheral blood lymphocytes from Epstein-Barr virus-nega-
tive donors. Eur J Immunol 22:3161—3166, 1992
33. Wu L, KINCADE PW, SHORTMAN K: The CD44 expressed on the
earliest intrathymic precursor population functions as a thymus hom-
ing molecule but does not bind to hyaluronate. Immuno! Lett 38:69—
75, 1993
34. LESLEY J, HOWES N, PERSCHL A, HYMAN R: Hyaluronan binding
Fricke et al: Peritoneal T lymphocytes 1395
function of CD44 is transiently activated on T cells during an in vivo
immune response. J Exp Med 180:383—387, 1994
35. ARCH R, WIRTH K, HOFMANN M, PONTA H, MATZKU S, HERRLIcII F,
ZOLLER M: Participation in normal immune responses of a metastasis-
inducing splice variant of CD44. Science 257:682—685, 1992
36. LESLEY J, HYMAN R, KINCADE PW: CD44 and its interaction with
extracellular matrix. Adv Immunol 54:271—335, 1993
37. KOOPMAN G, HEIDER KH, HORST E, ADOLF GR, vAN oBF, PONTA H,
HERRLICH P, PALS ST: Activated human lymphocytes and aggressive
non-Hodgkin's lymphomas express a homologue of the rat metastasis-
associated variant of CD44. J Exp Med 177:897—904, 1993
38. STAMENKOVIC I, ARUFFO A, AMIOT M, SEED B: The hematopoietic
and epithelial forms of CD44 are distinct polypeptides with different
adhesion potentials for hyaluronate-bearing cells. EMBO J 10:343—
348, 1991
39. OPPENI-IEIMER MN, DAvis LS, LIPSKY PE: Human T lymphocyte
adhesion to endothelial cells and transendothclial migration. Alter-
ation of receptor use relates to the activation status of both the T cell
and the endothelial cell. J Immunol 145:140—148, 1990
40. MACKAY CR, TERPE HJ, STAUDER R, MARSTON WL, STARK H,
GUNTHERT U: Expression and modulation of CD44 variant isoforms
in humans. J Cell Biol 124:71—82, 1994
41. ROSENBERG WM, PRINCE C, KAKLAMANIS L, Fox SB, JACKSON DG,
SIMMONS DL, CHAPMAN RW, TROWELL JM, JEWELL DP, BELL JI:
Increased expression of CD44v6 and CD44v3 in ulcerative colitis but
not colonic Crohn's disease. Lancet 345:1205—1209, 1995
42. GUNTHERT U, HOFMANN M, RUDY W, REBER 5, ZOLLER M, HAUSS-
MANN I, MATZKU S, WENZEL A, PONTA H, HERRLICH P: A new variant
of glycoprotein CD44 confers metastatic potential to rat carcinoma
cells. Cell 65:13—24, 1991
43. MULDER JWR, KRUYT PM, SEWNATH M, OOSTING J, SELDENRIJK CA,
WEIDEMA WF, OFFERHAUS GJA, PALs SA: Colorectal cancer prog-
nosis and expression of exon-v6-containing CD44 proteins. Lancet
344:1470—1472, 1994
44. MAYER B, JAUCH KW, GUNTI-IERT U, FIGDOR CG, SCHILDBERG FW,
FUNKE I, JOHNSON JP: De-novo expression of CD44 and survival in
gastric cancer. Lancet 342:1019—1022, 1993
45. STAUDER R, EISTERER W, THALEP. J, GUNTHERT U: CD44 variant
isoforms in non-Hodgkin's lymphorna: A new independent prognostic
factor. Blood 85:2885—2899, 1995
46. BAADSGAARD 0, TONG P, ELDER JT, HANSEN ER, Ho V, HAMMER-
BERG C, LANGE VG, Fox DA, FISHER G, CHAN LS, VOORHEES JJ,
COOPER KI: UM4D4+ (CDw6O) T cells are compartmentalized into
psoriatic skin and release lymphokines that induce a keratinocyte
phenotype expressed in psoriatic lesions. J Invest Dennatol 95:275—
282, 1990
47. Fox DA, MILLARD JA, KAN L, ZELDES WS, DAVIS W, HIGGS J,
EMMRICFI F, KINNE RW: Activation pathways of synovial T lympho-
cytes. Expression and function of the UM4D4/CDw6O antigen. J Clin
Invest 86:1124—1136, 1990
48. Fox DA, CHAN LS, KAN L, BAADSGAARD 0, COOPER KD: Expression
and function of the UM4D4 antigen in human thymus. J Immunol
143:2166—2175, 1989
